| Date | Time | Source | |
| 06/13/2013 | 9:00AM | GLOBE | XOMA Initiates Pilot Trial Studying Gevokizumab in Patients With Pyoderma Gangrenosum
BERKELEY, Calif., June 13, 2013 (GLOBE NEWSWIRE) -- XOMA Corporation (Nasdaq:XOMA), a leader in the discovery and development of therapeutic antibodies, today announced it has opened enrollment in a pilot study to determine gevokizumab's potential to treat acute inflammatory pyoderma gangrenosum. Pyoderma gangrenosum (PG... More...>> |
| 05/09/2013 | 12:00PM | ZACKS | Positive Data on Celgene's Apremilast - Analyst Blog
Celgene Corporation (CELG) recently announced positive results from the PALACE 4 study on apremilast. The study is evaluating apremilast (20 mg and 30 mg), a novel, oral small-molecule inhibitor of phosphodiesterase 4 (PDE4), in patients suffering from psoriatic arthritis. Results from the phase III study showed that apremilast... More...>> |
| 05/09/2013 | 11:50AM | ZACKS | ARNA Sheds Light on Belviq Launch - Analyst Blog
Arena Pharmaceuticals Inc. (ARNA) recently announced that the US Drug Enforcement Administration (DEA) has assigned its obesity drug Belviq into Schedule IV of the Controlled Substances Act. The company expects to make Belviq available in the US in a month. Upon commercialization of Belviq, Arena Pharma will receive $65... More...>> |
| 05/09/2013 | 4:16AM | ZACKS | VIVUS Reports Wider Loss - Analyst Blog
VIVUS Inc.’s (VVUS) first quarter 2013 loss of 53 cents per share was wider than the Zacks Consensus Estimate of a loss of 51 cents per share and the year-ago loss of 20 cents per share. The wider loss was due to higher operating expenses. The company’s net product revenue, consisting of Qsymia sales, for the... More...>> |
| 05/08/2013 | 4:01PM | GLOBE | XOMA Highlights Recent Achievements and Reports Financial Results for First Quarter 2013
BERKELEY, Calif., May 8, 2013 (GLOBE NEWSWIRE) -- XOMA Corporation (Nasdaq:XOMA), a leader in the discovery and development of therapeutic antibodies, today reported its operational highlights and financial results for the quarter ended March 31, 2013. Announced encouraging interim results from gevokizumab Phase 2 study... More...>> |
| 05/06/2013 | 2:30PM | GLOBE | XOMA to Present at Credit Suisse 2013 Antibody Day
BERKELEY, Calif., May 6, 2013 (GLOBE NEWSWIRE) -- XOMA Corporation (Nasdaq:XOMA), a leader in the discovery and development of therapeutic antibodies, announced today that Paul Rubin, the Company's Senior Vice President, Research and Development, and Chief Medical Officer, is scheduled to present at the Credit Suisse 2013... More...>> |
| 04/30/2013 | 12:30PM | ZACKS | CHMP Backs VIVUS' Spedra - Analyst Blog
VIVUS, Inc. (VVUS) recently announced the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of its drug, Spedra (avanafil) for the treatment of erectile dysfunction (ED). The positive opinion by the CHMP will be reviewed by the European Commission... More...>> |
| 04/26/2013 | 12:00PM | ZACKS | Bayer Earnings Rise Y/Y - Analyst Blog
Bayer’s (BAYRY) earnings during the first quarter of 2013 came in at €1.70 per share (approx. $2.24) compared with €1.67 per share (approx. $2.19) in the year-ago period. Earnings benefited from higher revenues. Bayer recorded 2.1% (3.7% on an adjusted basis) growth in revenues to €10.3 billion. The... More...>> |
| 04/26/2013 | 8:03AM | ZACKS | AstraZeneca Earnings Tumble Y/Y - Analyst Blog
AstraZeneca’s (AZN) first-quarter 2013 core earnings of $1.41 per American Depositary Share (ADS) beat the Zacks Consensus Estimate of $1.34. Earnings were down 21% (at constant exchange rates [CER]) year over year. AstraZeneca’s quarterly revenues fell 12% (at CER) year over year to $6.4 billion, primarily... More...>> |
| 04/25/2013 | 8:01AM | GLOBE | XOMA to Announce First Quarter 2013 Financial Results and Host Webcast on May 8
BERKELEY, Calif., April 25, 2013 (GLOBE NEWSWIRE) -- XOMA Corporation (Nasdaq:XOMA), a leader in the discovery and development of antibody therapeutics, announced the Company will host a conference call on Wednesday, May 8, 2013, at 4:30 p.m. Eastern time to discuss first quarter 2013 financial results and provide an update... More...>> |
| 04/23/2013 | 2:20PM | ZACKS | AZN/BIND Therapeutics Ink Deal - Analyst Blog
AstraZeneca (AZN) recently announced that it has entered into an agreement with BIND Therapeutics for the development and commercialization of Accurin (a cancer nanomedicine). As per the terms of the agreement, the companies will work together to complete studies to support the investigational new drug (IND) filing of... More...>> |
| 04/23/2013 | 10:43AM | ZACKS | Illumina Beats on Earnings, Revenue - Analyst Blog
Illumina Inc.’s (ILMN) first-quarter 2013 adjusted earnings of 46 cents per share beat the Zacks Consensus Estimate by 21%. Adjusted earnings grew almost 28% over the prior-year quarter driven by strong sales. However, including some one-time litigation expenses, its reported loss stood at 18 cents against a net... More...>> |
| 04/18/2013 | 2:55PM | ZACKS | AZN Inks Biomarker Discovery Deal - Analyst Blog
AstraZeneca (AZN) recently announced that it has entered into an agreement with UK-based company, Oxford Cancer Biomarkers Ltd. As per the terms of the agreement, Oxford Cancer Biomarkers Ltd. will work on an AstraZeneca oncology candidate to find biomarkers with potential to identify responders and non-responders to the... More...>> |
| 04/10/2013 | 8:00AM | GLOBE | XOMA Announces Clinical Study Investigating Gevokizumab in Patients With Non-Infectious Anterior Scleritis Has Opened for Enrol
BERKELEY, Calif., April 10, 2013 (GLOBE NEWSWIRE) -- XOMA Corporation (Nasdaq:XOMA), a leader in the discovery and development of therapeutic antibodies, today announced the National Eye Institute ("NEI"), one of the U.S. National Institutes of Health, has opened its non-infectious, active, anterior scleritis trial for... More...>> |
| 04/09/2013 | 12:40PM | ZACKS | Spectrum Progresses with SPI-2012 - Analyst Blog
Spectrum Pharmaceuticals (SPPI) recently initiated a phase II study on SPI-2012 (LAPS-GCSF). SPI-2012 is being developed for the treatment of chemotherapy-induced neutropenia which utilizes partner Hanmi Pharmaceutical Company's proprietary Lapscovery Technology. The multicenter, open label, dose-ranging study will... More...>> |
| 04/08/2013 | 1:28PM | ZACKS | Illumina Introduces TruSight Tumor - Analyst Blog
Recently, Illumina Inc. (ILMN) expanded its suite of TruSight content sets by adding TruSight Tumor to its portfolio. TruSight’s content set is created according to different diseases. Inherited disease, exome, cardiomyopathy, cancer and autism form an important part of TruSight’s content set. This new product... More...>> |
| 03/28/2013 | 2:10PM | ZACKS | Balanced View on Gilead Sciences - Analyst Blog
On Mar 26, 2013, we reiterated our Neutral recommendation on Gilead Sciences, Inc. (GILD) as we believe that the stock is fairly priced at current levels with limited scope for upside. The stock carries a Zacks Rank #3 (Hold) in the short run. Why the reiteration? In Feb 2013, Gilead delivered better-than-expected revenues... More...>> |
| 03/22/2013 | 5:50AM | ZACKS | More Protection for Biogen's Tecfidera - Analyst Blog
Biogen Idec (BIIB) recently announced additional patent protection for its oral multiple sclerosis candidate, Tecfidera (dimethyl fumarate). The company said that the US Patent and Trademark Office (USPTO) has granted US Patent No. 8,399,514 to Tecfidera. The recently issued patent, covering the daily dosing regimen of... More...>> |
| 03/19/2013 | 2:15PM | ZACKS | SGEN Seeks Adcetris Label Expansion - Analyst Blog
Seattle Genetics, Inc. (SGEN) recently announced the submission of a supplemental biologics license application (sBLA) to the US Food and Drug Administration (FDA) for the use of Adcetris (brentuximab vedotin) in the retreatment of patients and for extended duration of use beyond 16 cycles of therapy in relapsed Hodgkin... More...>> |
| 03/18/2013 | 2:22PM | DJN | XOMA Appoints Tom Klein to New Chief Commercial Officer Role
By Tess Stynes XOMA Corp. (XOMA) appointed Tom Klein, an industry veteran, to the newly created position of chief commercial officer as the drug developer said it is ready to begin building a strategy for the potential launch of its flagship product candidate. The company said Monday that starting at year's end XOMA expects... More...>> |
